About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 331 record(s)
Req # A-2020-000994
Records that exist in electronic form within Health Canada related to the COVID Alert app and Alberta. Exclude routine e-mail traffic but include reports, memos, presentations, briefing notes and emails related to the app and its delay in launching in Alberta from July 31, 2020 to October 14, 2020.Organization: Health Canada
April 2022
Req # A-2021-000384
Requesting the following information regarding medical device BLEScath Intratracheal Catheter (license no. 105680, device identifier 54-1100): The approved purpose/intended use of the device. The approved labelling. Published clinical literature that was supplied to Health Canada as a part of the medical device application, the title/citation of the articles referenced, or a copy of the literature itself.Organization: Health Canada
April 2022
Req # A-2021-000775
The Privacy Impact Assessment and/or the Privacy Compliance Evaluation that was performed regarding ArriveCAN mobile application pursuant to the Interim Directive on Privacy Impact Assessment from the Treasury Board.Organization: Health Canada
April 2022
Req # A-2021-001218
All comments received by the department relating to the draft Screening Level Risk Assessment for the Acyclic, Monocyclic and bicyclic monoterpenes Group.Organization: Health Canada
April 2022
Req # A-2021-001418
The letter New Brunswick Health Minister Dorothy Shephard wrote to Federal Health Minister regarding the neurological syndrome of unknown cause which would have been between October 1st and November 19th of 2021. All correspondence between the Federal health Ministers office and the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR) and the Government of New Brunswick officials from both the government and public health regarding the neurological syndrome in New Brunswick, between the dates and times of January 2020 & November 22nd 2021.Organization: Health Canada
April 2022
Req # A-2021-001446
The complete list of medical cannabis research that Health Canada has been involved in since the enacting of the original Marihuana Medical Access Regularions (MMAR) legislation, through to November 26th, 2021.Organization: Health Canada
April 2022
Req # A-2021-001454
Most recent publicly available product labelling available from Health Canada including package insert, label and carton for Flon Laboratories Inc. Dehydrated Alcohol (DIN 00394394) and Hospira Healthcare ULC Dehydrated Alcohol (DIN 00537640).Organization: Health Canada
April 2022
Req # A-2021-001603
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the cover letter from the drug sponsor.Organization: Health Canada
April 2022
Req # A-2021-001739
All records related to the Minister of Health's January 7, 2022 Public Briefing. Ensure that the January 6, 2022 Covid 19 B.1.1.529 Omicron Variant of Concern Response Placemat is included along with any other January 6, 2022 Covid 19 Variant of Concern Response Placemat.Organization: Health Canada
April 2022
Req # A-2021-001744
The brand name of the reference product and the dosage form of the generic submission under review for the combination of medicinal ingredients sulfamethoxazole and trimethoprim.Organization: Health Canada
April 2022